Fatemeh Sadabadi1, Aida Gholoobi2, Alireza Heidari-Bakavol3, Mohsen Mouhebati3, Ali Javandoost1, Zahra Asadi1, Maryam Saberi-Karimian1, Susan Darroudi1, Mohammad Sadegh Khorrami Mohebbseraj4, Farzad Rahmani1, Najmeh Malekzadeh Gonabadi5, Fatemehalsadat Jafari Sheshtamad1, Sara Samadi1, Afsane Bahrami6, Gordon Ferns7, Majid Ghayour-Mobarhan1,8, Habibollah Esmaeili9. 1. - Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Medical Genetics Research Centre, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Department of Medical Genetic and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Department of genetic, School of science, Sistan and Baluchestan University, Zahedan, Iran. 6. Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran. 7. Department of Medical Education, Brighton & Sussex Medical School, Brighton, BN1 9PH, UK. 8. International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 9. Department of Biostatistics & Epidemiology, School of Health, Management & Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally, and specifically in Iran. Generally, diabetes mellitus is the result of impaired glucose tolerance which together with dyslipidemia are considered as important risk factors of CVD. The aim of this study was to determine the relationship between fasting serum glucose (FSG), lipid profile and CVD endpoints, and to establish an optimal FSG cut-off in the MASHAD cohort study after nearly 6 years of follow-up. METHODS: All the participants of MASHAD study were followed up for 6 years to determine their cardiovascular status. FSG, fasting lipids, and physical examinations were all recorded. To identify the optimal cut- off point of FSG, we carried out receiver operating curve (ROC) analysis. RESULTS: We determined MASHAD cutoff point of blood glucose as 90 mg/dl predicting the CVD outcome. The sensitivity and specificity of the FSG criterion were 54.34% and 71.68%, respectively. The AUC was 0.665 (95% CI 0.656-0.675, P< 0.0001). The adjusted hazard ratio show that FSG is associated with 2.34 increase in CVD risk using MASHAD cutoff point (HR 2.34, 95% 1.73-3.17, P< 0.001). CONCLUSION: These findings suggest that not only FSG and lipid profile are related to CVD outcome in the MASHAD study, but also elevated fasting glucose levels is strongly associated with cardiovascular events in this population. Besides, the fasting glucose at a threshold of 90 mg/dl can be used for screening cardiovascular events among the Iranian population.
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally, and specifically in Iran. Generally, diabetes mellitus is the result of impaired glucose tolerance which together with dyslipidemia are considered as important risk factors of CVD. The aim of this study was to determine the relationship between fasting serum glucose (FSG), lipid profile and CVD endpoints, and to establish an optimal FSG cut-off in the MASHAD cohort study after nearly 6 years of follow-up. METHODS: All the participants of MASHAD study were followed up for 6 years to determine their cardiovascular status. FSG, fasting lipids, and physical examinations were all recorded. To identify the optimal cut- off point of FSG, we carried out receiver operating curve (ROC) analysis. RESULTS: We determined MASHAD cutoff point of blood glucose as 90 mg/dl predicting the CVD outcome. The sensitivity and specificity of the FSG criterion were 54.34% and 71.68%, respectively. The AUC was 0.665 (95% CI 0.656-0.675, P< 0.0001). The adjusted hazard ratio show that FSG is associated with 2.34 increase in CVD risk using MASHAD cutoff point (HR 2.34, 95% 1.73-3.17, P< 0.001). CONCLUSION: These findings suggest that not only FSG and lipid profile are related to CVD outcome in the MASHAD study, but also elevated fasting glucose levels is strongly associated with cardiovascular events in this population. Besides, the fasting glucose at a threshold of 90 mg/dl can be used for screening cardiovascular events among the Iranian population.
Authors: N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh Journal: Lancet Date: 2010-06-26 Impact factor: 202.731
Authors: Matthias Briel; Ignacio Ferreira-Gonzalez; John J You; Paul J Karanicolas; Elie A Akl; Ping Wu; Boris Blechacz; Dirk Bassler; Xinge Wei; Asheer Sharman; Irene Whitt; Suzana Alves da Silva; Zahira Khalid; Alain J Nordmann; Qi Zhou; Stephen D Walter; Noah Vale; Neera Bhatnagar; Christopher O'Regan; Edward J Mills; Heiner C Bucher; Victor M Montori; Gordon H Guyatt Journal: BMJ Date: 2009-02-16